Core Insights - Klotho Neurosciences, Inc. has signed a Letter of Intent to acquire select assets from Turn Biotechnologies, positioning itself as a leader in longevity therapeutics [1][4] - The acquisition includes Turn's ERA platform and eTurna RNA delivery system, aimed at rejuvenating somatic cells for various regenerative therapies [2][4] - Klotho will also gain a partnership with a South Korean pharmaceutical company valued at up to $300 million, highlighting the commercial potential of Turn's technology [3][4] Company Overview - Klotho Neurosciences focuses on developing innovative cell and gene therapies derived from the "anti-aging" Klotho gene, targeting neurodegenerative and age-related disorders [7] - The company aims to expand its therapeutic reach by integrating Turn's technologies, which utilize RNA molecules to reset cellular age [4][5] - Klotho plans to rebrand post-transaction to reflect its broadened mission in addressing aging and related diseases [4] Market Context - The longevity medicine market is rapidly growing, driven by an aging global population projected to reach 2.1 billion by 2050, significantly impacting healthcare costs [5] - Klotho aims to address aging at the cellular level, which is seen as a root cause of various age-related health issues [5]